Who mentions $CI most on Surfaced?

@theaiportfolios (The Claude Portfolio) mentions $CI most — 11 mentions in the past 12 months.

When was $CI first mentioned on Surfaced?

The earliest tracked mention of $CI in the Surfaced archive was on Mar 31, 2026.

How many voices track $CI?

2 FinTwit voices have mentioned $CI 12 times in the past 12 months.

What kind of voices mention $CI most?

$CI is mentioned most by Software voices on Surfaced.

$CI — FinTwit mentions on Surfaced

Recent mentions

12 mentions

@theaiportfoliosMay 1, 2026 · 5:15 PM

Breaking: Claude just bought a new stock and it's already up 8% Earlier this morning, Claude took our $50,000 and opened a brand new position in Ardelyx $ARDX Here's it's reasoning on why: "I initiated a new position in Ardelyx $ARDX at Friday's open, sized at 6.31% of the book. The core business is a specialty pharma compounder with two commercial products and accelerating revenue. IBSRELA is the only NHE3 inhibitor approved for IBS-C. The mechanism is distinct from the GC-C pathway that Linzess and Trulance use: NHE3 inhibition works through intestinal permeability and TRPV1 signaling, which matters for the roughly 30 to 40% of IBS-C patients who do not tolerate GC-C drugs. Q1 2026 revenue came in at $70.1M, up 58% year-over-year, with full-year guidance maintained at $410 to $430M. XPHOZAH, the renal drug for hyperphosphatemia, is adding paid prescriptions at +19% per quarter. The asymmetric edge is the Zydus filing. On April 24, Zydus Lifesciences registered "Zara Merger Sub Inc." on the BSE: a 100% Zydus-owned Delaware entity capitalized at $1,000. That is textbook M&A vehicle structure. Zydus has a Rs. 5,000 crore QIP approved by shareholders, with Jefferies, JPM, and IIFL Capital retained as advisors. The implied acquisition range based on precedent specialty pharma takeouts is $2.2 to $2.5 billion, representing a 60 to 90% premium to the pre-announcement trading range. Jefferies raised its price target from $8 to $15 on April 27, the most aggressive recent sell-side move, which I read as the street beginning to price this signal. The risk profile is why this position works inside the current portfolio context. Beta of 0.66 is the lowest among candidates with material expected return. The May binary cluster creates significant event-driven variance across the rest of the book. ARDX has no binary in the 90-day window. The catalysts are idiosyncratic: revenue execution on the FY26 guide and the Zydus M&A process. Neither is correlated to the Iran/Hormuz macro scenario or the Warsh rate-path risk that dominates the other positions. Expected: 1M +6.6% | 3M +22% | 12M +51.2%" New updated full portfolio: $NOW: 12.02% $VST: 10.08% $MSFT: 8.37% $LLY: 7.98% $CI: 7.11% $ARDX: 6.79% $ICE: 6.50% $RDDT: 6.20% $DVN: 5.78% $HALO: 5.68% $KTOS: 5.58% $NVDA: 4.99% $MA: 4.79% $QXO: 4.17% $AVGO: 3.96%

Open on X

@theaiportfoliosApr 27, 2026 · 2:52 PM

New: On Friday, Claude bought the dip on defense stocks by adding Kratos Defense to the portfolio It gave $KTOS a one month price target of $70.65 Today it's already up 4% Here's the reasoning on why it bought "I added Kratos Defense at 6% as a new position and a deliberate sector diversification. KTOS gives me exposure to a sector with a fundamentally different driver: government budget appropriations, not consumer or enterprise spending cycles. The thesis has two layers. First, the attributable drone franchise: Kratos makes the Valkyrie, Firejet, and Spartan systems that represent the Pentagon's bet on expendable, affordable airpower. The FY2027 DoD budget proposes $75B in drone spending, and the $200B Iran supplemental markup working through Congress adds to that. KTOS lost CCA Increment 1 to Anduril and General Atomics earlier this year. That loss is fully priced; the stock is down materially from its highs. The market treated the CCA loss as a verdict on KTOS's entire drone program. It's not. CCA is one competition; the broader drone procurement cycle is expanding. Second, the hypersonic test infrastructure: the MACH-TB contract ($1.45B ceiling) and the $446M Space Systems Command contract give KTOS a cash-generating legacy business that funds the venture bets in autonomous systems. This is not a pure speculative play on drones winning. The risks I'm accepting: 85x forward P/E is elevated. Free cash flow is negative $150 to $200M in FY2026. KTOS is not cheap, and it requires the Pentagon budget to materialize as proposed. May 6 Q1 earnings is the first in-window catalyst. I sized it at 6%, the midpoint of my sizing range, reflecting medium conviction with genuine upside asymmetry. Expected: 1M +15% | 3M +25% | 12M +58%" Updated full holdings of the portfolio: $NOW - 12.4% $VST - 10.3% $MSFT - 8.6% $LLY - 7.3% $CI - 7.1% $ICE - 6.5% $OKTA - 6.4% $RDDT - 6.1% $HALO - 5.8% $KTOS - 5.7% $DVN - 5.5% $NVDA - 5.2% $MA - 4.9% $QXO - 4.4% $AVGO - 3.9% See following tweet to verify full performance

Open on X

@theaiportfoliosApr 25, 2026 · 6:33 PM

The Claude Autonomous Agents have officially arrived. Three weeks ago we gave them a brand new $50,000 portfolio to see how well they do at investing in stocks. Their goal is to outperform the market. So far they have. Here's the stocks they own and the results thus far. Performance since inception Claude: +5.27% SPY: +4.74% It's made 7 new stock buys since April 1. And $14.7M is now investing alongside on Autopilot. Current holdings with performance 1. SERVICENOW $NOW +2.5% 2. Vistra $VST +2.0% 3. Microsoft $MSFT +7.6% 4. Eli Lilly & Co $LLY -10.1% 5. The Cigna Group $CI +1.4% 6. Intercontinental Exchange $ICE -2.8% 7. Okta $OKTA +1.1% 8. Reddit $RDDT -6.9% 9. Halozyme Therapeutics $HALO +4.8% 10. Kratos Defense $KTOS -7.8% 11. Devon Energy $DVN +6.6% 12. Nvidia $NVDA +10.0% 13. Mastercard $MA -3.1% 14. QXO, Inc $QXO -5.9% 15. Broadcom $AVGO +36.5% Commentary on previous trades Claude started off hot, outperforming the SPY by 4% plus through most of August. However it's recent trades have brought it back more in like with the SPY. It's recent buys of Reddit & Kratos in the last week have dragged the portfolio down. However, Broadcom being up 36% since it's first buy has kept the portfolio performing strong. Before it recently locked in profits last week, $AVGO was one of its largest positions. It also closed out positive gains in $AU and $GLD last week. Reasoning for recent top positions ServiceNow $NOW ServiceNow dropped 17.7% in one session after Q1 earnings. That is its worst single-day decline in a decade. I upsized from 7.55% to 11.55%. The quarter itself was good. Revenue of $3.77B grew 22% year over year. Management raised full-year subscription guidance by $205M. The actual deceleration in the underlying business is closer to 200bp. Deal timing in an active war zone is not deal loss. These are enterprise software contracts with multi-year terms: they are delayed, not canceled. The risk I'm accepting: if Q2 organic cRPO growth comes in below 18% constant currency, that would confirm structural AI-seat decay rather than a timing blip. That's the thesis-break signal. I'll be watching the Q2 guide at the May 4 Analyst Day for any preview of that number. Microsoft $MSFT Burry coming in long MSFT is a value-investor-turning-mega-cap-tech move, which is unusual for him. Different vehicle and process, similar setup read: post-drawdown entry on the highest-quality AI infrastructure name where the market is pricing the capex risk more aggressively than the demand backlog. The thesis: Azure has an $80B unfulfilled backlog with UK South denying compute requests. Supply-constrained, not demand-constrained. Copilot monetization just unblocked after the April 13 EA discount relaxations. At $424.62, MSFT trades at 22.0x fwd FY27 EPS vs 5-year average of 28x. Below GOOG (24x) and AMZN (26x). Comments on the broader project The goal of this new project is to put AI to the test and see if it can actually outperform with real money. All commentary found on the page is directly from Claude. Humans are only involved to copy/paste the communications Claude gives us via Slack to this page. Updates, performance, and commentary are shared here no matter if it performs or not. The portfolio is also listed on Autopilot so that followers can transparently verify the full performance of the portfolio to ensure all updates are true. Via Autopilot, followers who are interested can also connect their personal brokerage to invest alongside. So far $14,900,000 is Autopiloting the Claude Portfolio. See it all on the Autopilot app or via the first reply to this tweet. Happy Saturday y'all.

Open on X

@theaiportfoliosApr 21, 2026 · 5:51 PM

Breaking: Claude just bought the dip in Reddit $RDDT Three weeks ago, we set Claude's agents up with a brand new $50,000 portfolio So far its done well and is up 8% Today they bought a brand new stock 🟢 1. "BUY $RDDT Reddit — New Position at 6% "Reddit clears the swap-candidate bar for this cycle specifically bc it's the only new name where I can say "why now" and not just "why eventually. Reddit reports Q1 earnings on April 30 after close, exactly 10 days from entry. Short interest is 15 percent of float. Days-to-cover is 3.5. That is not buy-and-hold coverage. That is squeeze fuel if the Q1 guide holds. The bear thesis leaning on AI-traffic-bypass, the idea that ChatGPT and Gemini siphon Reddit traffic, either gets killed or validated in a single session. The one thing bulls and bears agree on is that the AI-data-licensing moat is real. Google paid to train Gemini on Reddit's corpus. That revenue stream did not exist two years ago, and it is still being under-modeled by the sell side. The factor diversification matters almost as much as the return. My book is currently 35 percent information technology across MSFT, NVDA, AVGO, NOW, OKTA, all rhyming on AI-capex and duration sensitivity. Reddit is Ad-spend driven. Different factor entirely. It diversifies the book meaningfully for the first time since I bought ICE." Expected: 1M a binary | 3M +20% | 12M +31.5% 🔴 1.SELL Booz Allen Hamilton $BAH Booz Allen was the only holding I already had flagged as a bearish-tilt. That status has been consistent since March 24, when my first portfolio review called BAH "the weakest thesis in the portfolio" and explicitly asked whether the position warranted reassessment. Two days later I upsized it from 5.3 to 6 percent on the Vellox AI cyber launch and the DOGE-redirects-spending-to-defense-primes thesis. That was the wrong call. The upsize did not get paid. The structural break is on the civilian government consulting side. BAH itself guided for a roughly 20 percent decline in civil revenue through fiscal 2026. The Treasury breach cost them a 21 million dollar contract. The Department of Defense canceled 4 billion dollars of wasteful spending in early April that has not yet been cycled through guidance. Updated holdings: $VST | 10.02% $NOW | 8.65% $MSFT | 8.34% (UPSIZE) $LLY | 7.52% $AVGO | 7.49% $CI | 6.92% $GLD | 6.78% $ICE | 6.53% $OKTA |6.35% $RDDT | 6.23% (NEW) $HALO | 6.10% $NVDA | 4.39% (TRIM) $DVN | 5.07% $MA | 4.87% $AU | 4.13% $BAH | 5.84% (EXIT) For those Autopiloting, your trades should have gone through automatically See following tweet for full performance

Open on X

@theaiportfoliosApr 16, 2026 · 2:31 PM

To save the timeline, the remaining picks + performance include: $VST: +1% $NVDA: +4% $LLY: +5% $GLD: +10% $ICE: 1% $CI: -2% $BAH: +6% $HALO: -2% $DVN: +1% $MA: 0%

Open on X

@theaiportfoliosApr 14, 2026 · 4:15 PM

Breaking: Claude just bought a new stock & made $NOW it's largest holding Last week we gave Claude agents $50,000 to see how well they do at picking in stocks So far, they've beaten the SPY by 4% Today they bought a brand new stock 🟢 1. "BUY $NVDA Nvidia — New Position at 5% WHY WE BOUGHT NVDA (NVIDIA CORPORATION) "The market spent the last several months giving investors a second chance to buy the most important infrastructure company in the AI era at a reasonable price. NVDA sits at $189, trading at 17x FY28 consensus earnings. Its semiconductor peers trade at 22x. The discount is real and documented Claude's analysis is that the market has priced all of this in and more, and that the net unpriced skew tilts bullish. The timing is driven by a catalyst calendar that is unusually dense. Every major hyperscaler reports earnings between April 22 and May 2 — these prints will confirm or challenge the $600B-plus aggregate AI capex thesis that underpins NVDA's revenue line. Any one of these events could serve as a re-rating trigger. The math: probability-weighted 12-month expected return of +37%, drawn from a base case of $260, a bull case of $350, and a bear of $140. The position is not a reach for a differentiated thesis; it is a straightforward argument that 17x for the dominant AI-compute platform with 85% GPU market share is too cheap, and that the catalyst calendar in April and May will demonstrate that." 🟢"2. INCREASED $NOW ServiceNow - Position is 12% WHY WE UPSIZED NOW (SERVICENOW) TO 12% "When one analyst downgrades a stock and the stock falls 45% in a matter of months, two things can be true simultaneously: the analyst might be right, and the market might have massively overreacted. Claude's research suggests the second is more likely. The UBS downgrade on April 10 argued that AI agents would displace enterprise workflow software incumbents. The counterpoint, laid out by Bernstein four days later, is that enterprise workflows exist precisely because organizations need audit trails, compliance records, and predictable process orchestration — the things agentic AI, by design, cannot reliably provide. NOW is not the thing agents replace; it is the system of record agents run on top of. The upsize from 8% to 12% was driven by valuation and by what happened after the downgrade. CEO Bill McDermott purchased $3 million of stock in the open market last week. Institutional 13F filings show position additions of 300% to 400% by multiple funds in the same window. The April 22 earnings print is the explicit clearing event. With five bulge-bracket price target cuts in the last seven days, the consensus bar going into the quarter is already on the floor. A clean quarter with maintained guidance is enough to begin a re-rate toward SaaS peer median. A beat-and-raise could take the stock from $89 to $120 in a single session. Claude's probability-weighted 12-month expected return is +41.3%, the highest conviction position in the book. The risk is binary: a cRPO miss of more than 300 basis points combined with a subscription guide cut to below 18% would confirm the bear case and trigger a cut to 4% or exit. That is the defined downside scenario, and it carries a 20% probability in the model. The position reflects that asymmetry." 🔴 "3. SELL $TMO Thermo Fisher — Full Exit WHY WE SOLD TMO (THERMO FISHER SCIENTIFIC) "Thermo Fisher was the quietest position in the portfolio. No thesis break, no scandal, no collapse in the business — just the steady accumulation of a case that the risk/reward no longer justified the slot. Claude's deep research today pegged the probability-weighted 12-month expected return at +5.3%, the lowest of any position in the book. At that level, TMO was a drag on the portfolio's opportunity cost even before considering the binary event bearing down on it. The deeper reason is that Claude runs a ranked expected-return framework. Every position competes against every other for a slot in a 15-stock portfolio. TMO at +5.3% was occupying 9% of the portfolio. That same capital deployed into NVDA (a swap candidate with +37.7% 12-month expected return) more than quadruples the expected return per dollar of exposure. When the math is that lopsided, and when the existing thesis is facing a near-term binary without asymmetric upside, the right call is a clean exit. TMO is a great business. It was not the right holding for this moment." New updated portfolio: $NOW | 12.4% $VST | 10.3% $LLY | 7.8% $AVGO | 7.3% $CI | 7.1% $GLD | 6.9% $ICE | 6.9% $BAH | 6.1% $HALO | 6.1% $OKTA | 5.6% $DVN | 5.5% $NVDA | 5.0% $MA | 4.9% $AU | 4.4% $MSFT | 4.1% Performance since inception: Claude: +4.2% SPY: +0.6% As a reminder, this is a public long term project to see how well Claude does We have 0 idea nor 0 expectation on how this will do, but we'll be sharing all updates here publicly and consistently no matter how good or bad Claude does See following tweet for information on how to invest alongside

Open on X

@theaiportfoliosApr 10, 2026 · 2:59 PM

Breaking: Claude just bought two new stocks bc of the March CPI print Last week we gave Claude agents $50,000 to see how well they do at picking in stocks So far, they've already outperformed the SPY Today, they just bought two new stocks: 🟢 1. "BUY $NOW ServiceNow — New Position at 8% ServiceNow is the portfolio's first direct entry into enterprise workflow SaaS, and we're initiating because the market just handed us a gift wrapped in a category error. On April 8, Anthropic launched Claude Managed Agents, a cloud-hosted AI agent platform for enterprise. The market read this as "AI will replace SaaS" and sold NOW down 7.56% to $89.53, a 52-week low. Down 58% from its high of $211. What the selloff missed: ServiceNow is an Anthropic design partner. Claude is the default model powering the ServiceNow Build Agent platform. This company is not a victim of the AI agent buildout. It is infrastructure for it. The valuation: 24x forward P/E against a 5-year average of 50 to 55x. That's a 50%+ discount to its own history. Still guiding roughly 20% subscription growth, 32% operating margins, 36% FCF margins. This is a strong business at an irrationally cheap multiple. Street consensus PT: $185, which is +107% from our entry. The risk that matters: Q1 guide cut to below 19% subscription growth would break the thesis and push the stock to $75-80. At 8% weight, that full bear outcome costs roughly 1.6% of portfolio. The base case delivers +2.4%. Today's CPI makes this entry even better. Core came in cool at +0.2% MoM and +2.6% YoY, below consensus. That's a direct tailwind for long-duration SaaS multiples. Rate cut odds improve on this core read." 🟢 "2. BUY $ICE Intercontinental Exchange — New Position at 7% ICE is the NYSE parent, the largest energy futures exchange, plus mortgage tech and fixed income data. About 55% of revenue is recurring subscriptions. March 2026 set the all-time monthly volume record: 428.9M contracts, +88% average daily volume. Oil futures up 85%. Rates futures up 140%. The Iran/Hormuz crisis is printing money for ICE's transaction business. Here's what makes ICE special in this portfolio: it wins in BOTH macro scenarios. Hormuz stays impaired? Energy vol stays elevated, transaction fees keep printing. Hormuz reopens cleanly? Fed gets room to cut, rate futures volume surges, mortgage tech recovers on the refi wave. There is no macro scenario where ICE loses. Valuation: 22.98x forward vs peer CME Group at 25.41x. Similar business, more diversification (mortgage tech, data), yet trades at a discount. UBS raised their Q1 EPS estimate to $2.26 versus street consensus of $2.00. That's a 13% beat baked into one analyst's model. Apr 30 Q1 earnings is the catalyst. The risk: $20.3B debt from the Black Knight acquisition. If rates stay higher for longer, the interest burden bites. And a clean Hormuz reopen would normalize energy volumes back to baseline. The record March was crisis-driven, not structural. Today's CPI is perfect for ICE. Gasoline +21.2% MoM (largest since 1967) plus a split headline/core narrative = maximum confusion in the rates market = maximum trading volume. ICE gets paid on the vol, not the direction." 🔴 "3. SELL $APO Apollo Global — Full Exit Apollo entered the portfolio as a high-quality alternative asset manager at a reasonable valuation. The thesis broke when a securities class action arrived and escalated fast. The case is Feldman v. Apollo, filed in SDNY. CEO Marc Rowan is directly named in Epstein discovery documents. This is categorically different from the 2020 Leon Black matter, which Apollo survived by installing new leadership. Here, Rowan IS the leadership. May 1 is the lead plaintiff deadline, and the recruitment phase is peaking. As of yesterday, 10+ law firms are actively soliciting plaintiffs. Goldman cut PT $169 to $134 on Apr 7. Piper Sandler cut $165 to $146. Barclays cut $131 to $125. Three bulge bracket cuts in 48 hours. Stanford/Cornerstone settlement math: 3-8% of the $12B February decline = $360M to $960M settlement range. Claude deep research estimates roughly 55% probability this tail is real and currently unpriced in consensus EPS. Three-week expected value runs negative 4% to negative 15%, skewed to the downside." 🔴 "4. SELL $GD General Dynamics — Full Exit General Dynamics was a defense prime with a $118B backlog, Columbia-class submarines, and the G800 ramp. The thesis was defense spending supercycle plus best-in-class execution. Three broker downgrades in one week. Deutsche Bank cut to Hold on Apr 7. Jefferies cut to Hold at $380 the same week. Citi had already cut to Neutral at $380 on Apr 2. All three cite the identical thesis: Q1 consensus revenue growth of +4% is roughly 300 basis points too high. Then the insiders. CEO Novakovic plus two EVPs sold $18.1M of stock on March 11, six weeks before the Apr 22 earnings print. When three analysts say the quarter will miss and the C-suite is dumping shares, you listen. BNP Paribas raised their PT to $430 on the same day Deutsche downgraded. The bull case exists. But it requires a fifth consecutive earnings beat that three of the most active defense desks now explicitly model as a miss. Expected 12M return: +4.3% probability-weighted. Below our portfolio hurdle. Firm score 82, the weakest tier among our holdings. The structural defense story (NATO 5% GDP, Columbia subs, Gulf stream backlog) is not dead. It's just 2-3 quarters away from showing in the numbers. We can re-enter at a better price after the Apr 22 print if the thesis repairs." New updated portfolio: $VST | 10.3% $TMO | 8.9% $LLY | 8.1% $NOW | 7.6% $AVGO | 7.3% $CI | 7.1% $GLD | 7.1% $ICE | 6.8% $HALO | 6.2% $BAH | 6.0% $OKTA | 5.7% $DVN | 5.6% $MA | 4.9% $AU | 4.4% $MSFT | 4.1% Performance since inception: Claude: +2.68% SPY: -0.25% As a reminder, this is a public long term project to see how well Claude does We have 0 idea nor 0 expectation on how this will do, but we'll be sharing all updates here publicly and consistently no matter how good or bad Claude does See following tweet for information on how to invest alongside

Open on X

@theaiportfoliosApr 9, 2026 · 3:30 PM

Transparency performance update Since inception on 3/4/26, Claude is outperforming the SPY and has already made $1,760. Claude +3.52% SPY -0.82% 1,335 investors have Autopiloted $4,300,000+ alongside too Here's the performance of each: 1. Broadcom $AVGO +14.3% 2. Vistra Energy $VST -0.5% 3. Thermo Fisher $TMO -1.6% 4. Eli Lilly $LLY -3.3% 5. Cigna $CI +1.9% 6. Gold $GLD +9.2% 7. Okta $OKTA -6.5% 8. Booz Allen $BAH +1.6% 9. General Dynamics $GD -5.1% 10. Devon Energy $DVN +8.9% 11. Mastercard $MA -3.9% 12. Apollo $APO -1.6% 13. Anglogold $AU +24.4% 14. Microsoft $MSFT -1.3% Looks like even through the volatility, the portfolio has held it's own Again, we have 0 idea on how this will go but will be sure to consistently publish all data + updates here So follow along for more to come

Open on X

@theaiportfoliosApr 7, 2026 · 7:40 PM

Breaking: Claude just made it's first trade Last week we gave Claude agents a new $50,000 portfolio to see how well they do at picking in stocks So far, they've already outperforming the SPY Today, it just bought it's newest stock: "WHY WE SOLD $HWM (Howmet Aerospace) Howmet was our only Hold-rated position out of 15. At 63.7x trailing P/E — twice the aerospace peer average — the stock was priced for perfection with no margin for error. Our research projected just +2.3% over 12 months. That barely beats the S&P. For a position carrying this much concentrated risk, that return doesn't justify the capital. The near-term setup made it worse. The company declared force majeure on tariffs, threatening to halt shipments to Boeing and Airbus. They just closed a $1.8B acquisition funded by $1.2B in new debt, adding leverage at exactly the wrong time. And insiders sold 6 times in the past year with zero purchases. When your weakest position barely beats a savings account, has the highest P/E in the portfolio, and management is selling — that's your exit." WHY WE BOUGHT $MSFT (Microsoft) "Microsoft is trading at 19.7x forward earnings. That's 34% below the software sector average and the cheapest the stock has been relative to peers in over 5 years. The stock is down 28% from its highs — a rare entry point into the world's largest enterprise cloud platform. The edge is timing. Q3 earnings land April 28 with Azure guided at 37-38% growth. The company has $625B in revenue backlog and Copilot has hit 4.7M paid seats. This is not a turnaround story — it's a quality compounder temporarily mispriced by macro fear. The risk is capex. Microsoft is spending $100B+ this year on AI infrastructure, which compresses free cash flow in the near term. If Azure decelerates or the UK CMA forces Office unbundling, the multiple stays depressed longer. But the math was clear: MSFT at +22.1% expected return vs HWM at +2.3%. That was the widest gap in the entire portfolio — a 10x difference in projected return. The swap uses 8.14% of our 10% turnover budget. One clean, high-conviction move." New updated portfolio: $AVGO | 10.05% $VST | 9.99% $TMO | 8.84% $LLY | 7.98% $CI | 7.16% $OKTA | 7.09% $GLD | 6.89% $BAH | 6.37% $GD | 6.08% $DVN | 5.86% $HALO | 5.80% $MA | 4.97% $APO | 4.72% $AU | 4.13% $MSFT | 4.07% Performance since inception: Claude: +1.60% SPY: -3.4% As a reminder, this is a public long term project to see how well Claude does We have 0 idea nor 0 expectation on how this will do, but we'll be sharing all updates here publicly and consistently no matter how good or bad Claude does

Open on X

@theaiportfoliosApr 2, 2026 · 5:18 PM

6. The Cigna Group $CI - 7% Deeply undervalued managed care at 9x forward P/E vs. its 5-year average of 17x. BofA named CI its top MCO pick FTC PBM settlement resolved; Clearity precision medicine model is a first-mover advantage https://t.co/AXGqQD12yI

Open on X

@theaiportfoliosApr 1, 2026 · 3:34 PM

Introducing the 15 stocks it picked: Vistra $VST 10% Broadcom $AVGO 10% Thermo Fisher $TMO 9% Eli Lilly $LLY 8% Gold $GLD 7% Cigna $CI 7% Okta $OKTA 7% Devon $DVN 6% Booz Allen $BAH 6% Halozyme $HALO 6% Apollo $APO 5% Mastercard $MA 5% Howmet $HWM 4% AngloGold $AU 4%

Open on X

@investmentguru_Mar 31, 2026 · 10:58 AM

UNDERVALUED STOCKS RIGHT NOW $MU → Price: ~$320 | Fwd P/E: 3.94x → Q2 FY26 revenue +196% YoY, EPS +682% → AI HBM memory demand exploding → Analyst avg target: $443 (+34% upside) $PYPL → Price: ~$44 | P/E <10x → Processes $1.8T in annual payment volume → ~$5-6B free cash flow/year → Trading 41% below 52-week high → Analyst avg target: $64 (+43% upside) $CMCSA → Price: ~$28 | Div yield: 4.4% → Beat Q4 EPS by 15% ($0.84 vs $0.73 est.) → Streaming + wireless growth accelerating → Trading near multi-year lows → BofA maintains Buy rating $ADBE → Price: ~$240 | Analyst avg target: $344 → AI integration into Creative Cloud driving retention → Fwd P/E significantly below sector peers → Fair value upside flagged at 45%+ $CI → Price: ~$258 → Healthcare giant, P/E <10x → Strong cash generation, consistent buybacks → Highlighted by InvestingPro with 25%+ fair value upside → One of the cheapest large-cap health names on the market $ACN → Price: ~$197 → Mid-cap tech/consulting leader → Fair value upside >45% per multiple models → AI consulting demand ramping across enterprise → Flagged across InvestingPro, Kavout, https://t.co/ubdnld9Ygl screeners $GM → Price: ~72 → Q4 beat, +13% EPS growth guidance for 2026 → $6B buyback + 20% dividend hike announced → Massively undervalued vs. fundamentals $VZ → Price: ~$50 | Div yield: ~6%+ → Defensive income play, deeply discounted vs. peers → Low P/E, high FCF, stable subscriber base → One of the lowest-multiple names in large-cap telecom ⚠️ Not financial advice. DYOR.

Open on X

$CI

$CI

About this stock

Related stocks

Frequently asked